



Choosing a Therapeutic Approach to Early-Onset Schizophrenia: Disease Assessment to Pharmacotherapy

Participate in the CME/CE-certified multimedia activity featured in this podcast. Go online now at:

www.peerviewpress.com/pc2/p139

Program Faculty

Course Director

Robert L. Findling, MD
University Hospitals Case Medical Center
Case Western Reserve University
Cleveland, Ohio

CME/CE Reviewer

Andrew F. Leuchter, MD
David Geffen School of Medicine at UCLA
Semel Institute for Neuroscience and Human Behavior at UCLA
Los Angeles, California



UCLA



This CME/CE activity is sponsored by the Semel Institute for Neuroscience and Human Behavior at UCLA in association with PVI, PeerView Institute for Medical Education.



This activity is supported by an educational grant from Bristol-Myers Squibb Company.

To complete the post-test and evaluation for CME/CE credit please click here: www.peerviewpress.com/pc2/p139

Choosing a Therapeutic Approach to Early-Onset Schizophrenia: Disease Assessment to Pharmacotherapy

Participate in the CME/CE-certified multimedia activity featured in this podcast.
Go online now at:

www.peerviewpress.com/pc2/p139

General Information

Requirements for Successful Completion:

In order to receive credit, participants must view all audio-visual presentations and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CE credit. Certificates are awarded upon successful completion of the post-test and evaluation form.

Media:	Internet
Release Date:	April 18, 2008
Expiration Date:	April 17, 2009
Estimated time to complete activity:	60 minutes
Sponsorship:	This CME/CE activity is sponsored by the Semel Institute for Neuroscience and Human Behavior at UCLA in association with PVI, PeerView Institute for Medical Education.
Support:	This activity is supported by an educational grant from Bristol-Myers Squibb Company.

Faculty Disclosures/Conflict of Interest Policy

In accordance with ACCME requirements, the Semel Institute for Neuroscience and Human Behavior at UCLA, has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Robert L. Findling, MD, has a financial interest/relationship or affiliation in the form of: Consultant for Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Cypress Bioscience, Inc. Eli Lilly and Company; Forest Laboratories Inc.; GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; New River Pharmaceuticals Inc.; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals USA Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; sanofi-aventis; Sepracor Inc.; Shire Pharmaceuticals Group plc; Solvay Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; and Wyeth Pharmaceuticals Inc.
Grant/Research Support from Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Neuropharm Group plc; New River Pharmaceuticals Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Shire Pharmaceuticals Group plc; and Wyeth Pharmaceuticals Inc.
Speakers Bureau participant with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Shire Pharmaceuticals Group plc.

CME/CE Reviewer: Andrew F. Leuchter, MD, has a financial interest/relationship or affiliation in the form of:

Consultant for Aspect Medical Systems; Eli Lilly and Company; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; and Shire Pharmaceuticals Group plc.
Grant/Research Support from Aspect Medical Systems; Eli Lilly and Company; MedAvante, Inc.; Merck & Co., Inc.; Pfizer Inc.; and Vivometrics, Inc.
Speakers Bureau participant with Bristol-Myers Squibb Company; Eli Lilly and Company; and Wyeth Pharmaceuticals.

To complete the post-test and evaluation for CME/CE credit
please click here: www.peerviewpress.com/pc2/p139

Choosing a Therapeutic Approach to Early-Onset Schizophrenia: Disease Assessment to Pharmacotherapy

Participate in the CME/CE-certified multimedia activity featured in this podcast.
Go online now at:

www.peerviewpress.com/pc2/p139

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Target Audience

This activity has been designed to meet the educational needs of pediatricians, psychiatrists, nurses, and pharmacists who treat children and adolescents with early-onset schizophrenia.

Program Description

In this activity, an expert in the area of early-onset schizophrenia discusses the diagnosis and treatment of this condition, as well as the management of adverse events.

Educational Objectives

Upon completion of this activity, participants will be able to:

- Describe the differential diagnosis of schizophrenia in children and adolescents
- Select appropriate pharmacologic and nonpharmacologic treatment for children or adolescents with early-onset schizophrenia
- Identify potential long-term complications associated with atypical antipsychotics that may potentially alter the selection of therapy for children or adolescents with schizophrenia

Accreditation and Credit Designation Statements

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by the Semel Institute for Neuroscience and Human Behavior at UCLA in association with the PeerView Institute for Medical Education (PVI). The Semel Institute for Neuroscience and Human Behavior at UCLA is accredited by the California Medical Association (CMA) to provide continuing medical education for physicians. Physicians attending this course may report up to 1.0 hour(s) of Category I credit(s) toward the CMA's Certification in Continuing Medical Education and the American Medical Association's Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

The Semel Institute at UCLA is an accredited provider for continuing education credits for nurses (provider number CEP381). This course meets the qualifications for 1 hour of credit as required by the Board of Registered Nursing.

To complete the post-test and evaluation for CME/CE credit
please click here: www.peerviewpress.com/pc2/p139

Choosing a Therapeutic Approach to Early-Onset Schizophrenia: Disease Assessment to Pharmacotherapy

Participate in the CME/CE-certified multimedia activity featured in this podcast.
Go online now at:

www.peerviewpress.com/pc2/p139

Pharmacists

The Semel Institute at UCLA is approved by the American Council of Pharmacy Education as a provider of continuing pharmacy education. This program is accredited for 1.0 contact hour(s), Universal Program Number 291-000-08-001-H01-P. This activity was planned and produced in accordance with the Criterion and Standards of ACPE. In order to receive credit, participants must attend the entire activity.

Hardware/Software Requirements

PeerView Press requires version 6.x browsers or higher from Microsoft or Netscape. Certain activities may require additional software to view. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Reader®, and Adobe® Flash Player.

Privacy Policy

PeerView Press shares your concerns about maintaining the privacy of personal information collected on the Internet. PeerView Press ensures that confidentiality of data relating to individual visitors to a medical/health web site, including their identity, is respected by this web site. The web site owners undertake to honor or exceed the legal requirements of medical/health information privacy that apply in the country and state where the web site and mirror sites are located.

Privacy Policy Changes:

Minor changes to our privacy policy may occur. If privacy policies change in a way that significantly affects the way we handle personal information, we will not use the information we have previously collected without obtaining consent. We will post all privacy policy changes on our web site in a timely manner.

Collection of Personal Information from Site Users:

Visitors to PeerView Press can access and browse the site, without disclosing any personally identifiable information. PeerView Press does track some information provided by your browser, such as the time and date of access, the web site you came from, the type of browser used, and other information that does not personally identify you. Visitors registering for services such as email updates, or completing program evaluation forms are requested to provide personal information, such as name, contact information, and medical specialty. We clearly label which information is required for registration, and which information is optional, on our registration forms. PeerView Press will not collect personally identifiable information without consent and will not share this data with any external partners.

[Click here to see the full PeerView Press Privacy Policy](#)

Disclaimer

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

To complete the post-test and evaluation for CME/CE credit
please click here: www.peerviewpress.com/pc2/p139